Brokerages Set NGM Biopharmaceuticals (NYSE:NGM) Price Target at $30.33

Shares of NGM Biopharmaceuticals (NYSE:NGM) have earned an average rating of “Buy” from the seven research firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $30.33.

NGM has been the topic of a number of analyst reports. Stifel Nicolaus reissued a “buy” rating and issued a $32.00 price target on shares of NGM Biopharmaceuticals in a research note on Monday, May 18th. B. Riley restated a “buy” rating and issued a $30.00 price objective on shares of NGM Biopharmaceuticals in a research report on Thursday, May 21st. Raymond James upped their price objective on shares of NGM Biopharmaceuticals from $31.00 to $32.00 and gave the company a “strong-buy” rating in a research report on Thursday, May 14th. Zacks Investment Research cut shares of NGM Biopharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, May 19th. Finally, Cowen restated a “buy” rating and issued a $30.00 price objective on shares of NGM Biopharmaceuticals in a research report on Monday, March 23rd.

Shares of NGM stock traded down $2.79 during trading hours on Tuesday, reaching $19.58. The company had a trading volume of 711,100 shares, compared to its average volume of 343,334. The company has a 50 day moving average of $21.24 and a 200 day moving average of $17.86. NGM Biopharmaceuticals has a 1-year low of $8.81 and a 1-year high of $23.95.

NGM Biopharmaceuticals (NYSE:NGM) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.28) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.27) by ($0.01). The firm had revenue of $24.36 million during the quarter, compared to the consensus estimate of $19.92 million.

In other NGM Biopharmaceuticals news, SVP Hsiao D. Lieu sold 1,562 shares of the stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $22.00, for a total transaction of $34,364.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jin-Long Chen sold 25,000 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $21.65, for a total value of $541,250.00. The disclosure for this sale can be found here. In the last quarter, insiders have acquired 527,877 shares of company stock valued at $7,133,614.

Several hedge funds and other institutional investors have recently made changes to their positions in NGM. Bank of Montreal Can grew its holdings in shares of NGM Biopharmaceuticals by 412.9% in the 4th quarter. Bank of Montreal Can now owns 3,072 shares of the company’s stock valued at $57,000 after acquiring an additional 2,473 shares in the last quarter. Sowell Financial Services LLC bought a new position in shares of NGM Biopharmaceuticals in the 4th quarter valued at about $61,000. Acadian Asset Management LLC bought a new position in shares of NGM Biopharmaceuticals in the 1st quarter valued at about $66,000. BNP Paribas Arbitrage SA grew its holdings in shares of NGM Biopharmaceuticals by 165.7% in the 1st quarter. BNP Paribas Arbitrage SA now owns 7,540 shares of the company’s stock valued at $93,000 after acquiring an additional 4,702 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of NGM Biopharmaceuticals in the 4th quarter valued at about $101,000.

NGM Biopharmaceuticals Company Profile

NGM Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include Aldafermin, an engineered variant of the FGF19 human hormone in Phase 2b clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b clinical trial for use in the treatment of type 2 diabetes and NASH; and NGM395, which is engineered variant of the GDF15 human hormone for use in the treatment of metabolic syndrome.

Featured Story: Return on Investment (ROI) Defined, Explained

Analyst Recommendations for NGM Biopharmaceuticals (NYSE:NGM)

Receive News & Ratings for NGM Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NGM Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.